Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Yiling Pharmaceutical's Patent Depression-resolving Drug Approved for Marketing in China
Details : According to the decreased values for main efficacy indicators of the Hamilton Depression Scale scores from the baseline, the efficacy of the test group was better than that of the placebo group, and also not inferior to that of the fluoxetine hydrochlor...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 22, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lisinopril
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Preparation Products of Yiling Pharma Approved by FDA for Launch in the US Market
Details : The announcement showed that Lisinopril Tablets are mainly used for the treatment of essential hypertension (EH) and renal vascular hypertension (RVH) and were originally researched and developed by Astrazeneca and approved for launch in the United State...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 19, 2020
Lead Product(s) : Lisinopril
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lianhua Qingwen
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lianhua Qingwen Receives First International Approval for Covid-19 Treatment
Details : Lianhua Qingwen Capsules was approved to be registered as a drug to treat symptoms like fever, cough, debilitation, sore muscles, nasal obstruction, runny nose, headaches, a dry and sore throat, shortness of breath, and a red tongue caused by viral disea...
Product Name : KT07
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 09, 2020
Lead Product(s) : Lianhua Qingwen
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable